Strides Pharma Science reports a consolidated net profit of Rs 93.66 crore in Q2 FY25, a turnaround from a loss in the same period last year. Revenue also increased, driven by new product launches and strong US operations.
New Delhi, Oct 24 (PTI) Strides Pharma Science Ltd on Thursday reported a consolidated net profit of Rs 93.66 crore in the second quarter ended September 2024.
The company had posted a net loss of Rs 149.45 crore in the corresponding period last fiscal, Strides Pharma Science said in a regulatory filing.
Revenue from operations in the quarter under review stood at Rs 1,201.11 crore as against Rs 999.43 crore in the year-ago period, it added.
Total expenses in the second quarter were higher at Rs 1,097.98 crore as compared to Rs 984.99 crore in the same period a year ago.
Q2FY25 demonstrated sustained growth across all markets fuelled by new product launches. US operations reported the highest-ever quarterly revenue of USD 75 million in Q2FY25, Strides Pharma Science Founder & Executive Chairperson Arun Kumar, and MD & Group CEO Badree Komandur said.
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.
© 2024 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback